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Radiobiological modeling
suggests that dose escalation
to the gross tumor volume in
esophageal cancer has the
potential to produce signifi-
cant gains in tumor control
with only a minor increase in
lung or heart toxicity for the
majority of patients. The
relationship between tumor
response and normal tissue
toxicity during dose escala-
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http://dx.doi.org/10.1016/j.ijrobp.2014.06.028Purpose: This study investigated the trade-off in tumor coverage and organ-at-risk
sparing when applying dose escalation for concurrent chemoradiation therapy
(CRT) of mid-esophageal cancer, using radiobiological modeling to estimate local
control and normal tissue toxicity.
Methods and Materials: Twenty-one patients with mid-esophageal cancer were
selected from the SCOPE1 database (International Standard Randomised Controlled Tri-
als number 47718479), with a mean planning target volume (PTV) of 327 cm3. A boost
volume, PTV2 (GTV þ 0.5 cm margin), was created. Radiobiological modeling of tu-
mor control probability (TCP) estimated the dose required for a clinically significant
(þ20%) increase in local control as 62.5 Gy/25 fractions. A RapidArc (RA) plan with
a simultaneously integrated boost (SIB) to PTV2 (RA62.5) was compared to a standard
dose plan of 50 Gy/25 fractions (RA50). Dose-volume metrics and estimates of normal
tissue complication probability (NTCP) for heart and lungs were compared.
Results: Clinically acceptable dose escalation was feasible for 16 of 21 patients, with sig-
nificant gains (>18%) in tumor control from 38.2% (RA50) to 56.3% (RA62.5), and only a
small increase in predicted toxicity: median heart NTCP 4.4% (RA50) versus 5.6%
(RA62.5) P<.001 and median lung NTCP 6.5% (RA50) versus 7.5% (RA62.5) P<.001.
Conclusions: Dose escalation to the GTV to improve local control is possible when over-
lap between PTVand organ-at-risk (<8% heart volume and<2.5% lung volume overlap
for this study) generates only negligible increase in lung or heart toxicity. These, Department of Oncology,
ogy, University of Oxford,
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Chemoradiation therapy (CRT) is becoming established as
an effective treatment for locally advanced esophageal
cancer, as a neoadjuvant strategy for operable adenocarci-
nomas or as a definitive treatment when there is a high risk
of surgical morbidity and mortality (1). Long-term survival
for operable squamous cell carcinomas treated with defin-
itive CRT (dCRT) is comparable to surgery alone (2).
Although CRT is more effective than either radiation
therapy or chemotherapy alone (3, 4), locoregional control
rates with the standard radiation therapy dose of z50 Gy
are still low, and >75% of failures occur within the gross
tumor volume (GTV) (5, 6).
A correlation between higher dose and improved tumor
control and survival was described by Zhang et al (7) when
patients were divided into low-dose (51 Gy) and high-
dose (>51 Gy) groups. Further evidence of a radiation
dose response has been found by a systematic review (8),
which looked at rates of pathological complete response
(pCR) in preoperative CRT. Fitting the data to a radiobio-
logical model suggested that increasing the radiation dose
prescription from the standard z50 Gy could result in
significant improvement in tumor control probability
(TCP).
Conversely, data from a phase 3 clinical trial, Radiation
Therapy Oncology Group (RTOG) 9405, investigating the
use of higher radiation dose (64.8 Gy) versus standard dose
(50.4 Gy) found no improvement in survival or local con-
trol, and a relatively high comorbidity in the high-dose arm
(9). However, the radiation therapy treatment technique at
this time was based on 2D planning (using relatively large
treatment fields) and a sequential dose boost regimen.
Occurrence of several deaths in the high-dose arm before
reaching 50.4 Gy has limited further investigation of dose
escalation in spite of general understanding of 2D planning
insufficiency.
The role of radiation therapy dose escalation in
improving outcomes for definitive CRT has been recently
identified as one of the priorities for research in esophageal
cancer in the United Kingdom (10). Nevertheless, the
optimal combination of radiation therapy and chemo-
therapy doses needs to be carefully established in order to
improve locoregional control.
Long-term toxicities, particularly to the cardiorespira-
tory system have been described following dCRT for
esophageal cancer. Acute toxicity related to substructures
of the heart has been studied specifically, for example,
pericardial effusion (onset within 6 months) (11-13). These
studies suggest a higher mean pericardial dose is associated
with increased risk of pericardial effusion. Left ventricular
mean dose (14) has also been found to be related to acutecardiac impairment observed by MRI for patients under-
going CRT for esophageal cancer. Radiobiological models
of long-term cardiac toxicity have also been presented
using dose to whole heart (15).
Radiation-induced lung toxicity is important, not just as
a result of the proximity of lung tissue to the esophageal
target volume (16) but also as newer radiation therapy
techniques such as IMRT or volumetric arc, generate a low
dose bath to a large region of lung tissue. Recent studies of
lung cancer also indicate that radiation-induced lung
toxicity may be related to either pre-existing cardiac co-
morbidity (17) or to concomitant irradiation of the heart
(18). Although the biological mechanism is as yet unclear,
there is a statistically significant association between risk of
radiation pneumonitis and dose-volume variables for both
heart and lung for these patients.
This study had 2 aims: (1) to estimate the level of dose
escalation required for a clinically significant increase in
tumor control using radiobiological modeling across a
group of representative patients, and to examine whether
this dose could be safely delivered by calculating normal
tissue complication probability (NTCP) for heart and lungs;
and (2) to evaluate the feasibility of a clinical trial using
dose escalation for esophageal cancer patients treated with
definitive CRT by comparing results for individual patients.
Methods and Materials
A subset of 21 mid-thoracic esophageal cancer patients
(10% of the total radiation therapy group) was selected
from the SCOPE1 database (ISRCTN 47718479). This
subset had a range of planning target volumes of 140-591
cm3 (Table 1) and a mean PTV (327 cm3) consistent with
the entire original cohort (mean 334 cm3). Trial-derived
gross tumor volumes (GTV) were used, and visual assess-
ment of normal tissue contours was undertaken. The
SCOPE protocol standard margins were re-applied without
modification to generate the clinical target volume (CTV)
and planning target volume (PTV1) (19). Several additional
volumes were contoured: PTV2 (boost volume) created by
adding a 0.5 cm margin in all directions to the GTV, and a
pericardium structure comprised of a 1 cm rind inside (12)
the whole heart outline.
Radiobiological modeling of TCP to determine the level
of dose escalation to the GTV was carried out using the
parameters from Geh et al (8). This is a multivariate logi-
sitic regression model fitted to data from 26 CRT trials for
preoperative esophageal cancer. Analysis was based on the
protocol-prescribed doses of radiation therapy and chemo-
therapy (5-fluorouracil and cisplatin) to predict the TCP
(TCP Geh) of pCR, and included total dose, dose per
fraction and duration among the fitting parameters. The
Table 1 Patient target volume characteristics and overlap
with heart and lung structures in order of increasing PTV1
size*
Patient
Volume (cm3) % Volume overlap
GTV PTV2 PTV1
Lung in
PTV1
Heart in
PTV1
1 4.7 18.4 140.1 0.5 1.0
2 4.1 16.7 146.8 1.0 4.9
3 7.2 28.8 195.2 0.2 6.7
4 10.5 32.7 195.6 0.5 5.5
5 8.8 29.0 205.2 0.4 7.6
6 15.3 43.4 218.6 0.4 3.8
7 12.1 43.1 233.4 0.2 9.6
8 16.5 48.9 239.0 0.8 5.2
9 27.7 66.1 297.7 2.0 8.6
10 30.2 71.6 301.1 1.3 6.3
11 23.3 66.1 311.7 0.8 16.5
12 29.3 76.8 329.8 2.0 4.6
13 37.2 92.7 356.1 0.8 4.6
14 45.1 101.2 374.9 0.5 5.5
15 52.3 111.0 405.2 1.9 4.9
16 43.9 105.3 408.8 2.5 8.2
17 46.0 109.8 434.2 1.4 11.3
18 35.4 94.1 443.1 1.5 3.6
19 65.5 140.3 453.6 1.7 2.6
20 95.4 175.2 544.9 1.8 5.0
21 104.4 199.5 590.8 3.2 8.5
Abbreviations: GTVZ gross tumor volume; PTVZ planning target
volume.
* Patients for whom dose escalation was unsuccessful are marked in
boldface type.
Table 2 Dose constraints used in treatment planning for
RA50 and RA62.5 radiation therapy plans
Dose-volume Constraint
PTV1 (50 Gy) V95% (47.5 Gy) > 95%
Dmax (0.1 cc) < 107% (53.5 Gy)
PTV2 (GTV þ 0.5 cm)
(62.5 Gy)
V95% (59.375 Gy) > 95%
Dmax (0.1 cc) < 107% (66.875 Gy)
Lung Mean dose < 20 Gy
V20Gy < 25%
Heart Mean dose < 25 Gy
V30Gy < 45%
CordPRV Dmax (0.1 cc) < 40 Gy (45 Gy
permitted)
Abbreviations: CordPRV Z Cord planning organ at risk volume;
DmaxZ maximum dose; RA50Z RapidArc plan to 50 Gy; RA62.5Z
RapidArc plan with boost to 62.5 Gy; V30GyZ volume receiving 30 Gy.
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listed in the original paper (8).
TCPðzÞZ expðzÞ
1þ expðzÞ
where
zZa0 þ a1 total RT doseþ a2 total RT dose
 dose per fractionþ a3 durationþ a4 age
þ a5 5FU doseþ a6 cisplatin dose
A clinically significant 20% increase in local control
requires 67.0 Gy, but this would considerably lengthen the
total treatment time if delivered in 2-Gy fractions. We
therefore calculated the equivalent dose to be delivered in
25 fractions (2.5 Gy per fraction) as 62.5 Gy, maintaining
the same duration (33 days) as the standard plans of 50 Gy.
Treatment planning was performed using Eclipse,
version 10 (Varian, Palo Alto, CA). RapidArc (RA) plans
were created using 2 arcs of 360, clockwise and counter-
clockwise, with a collimator rotation of 10. Dose
calculation was performed using the AAA algorithm using
a 2.5-mm grid. A standard plan (RA50) was created (dose
prescription 50 Gy/25 fractions to PTV1) and compared to
a plan with an additional simultaneously integrated boost
(SIB) of 62.5 Gy to PTV2 (RA62.5). Dose constraints arelisted in Table 2, and additional dose-volume metrics were
recorded for pericardium (mean dose, V30Gy, V45Gy) and
lung V13Gy.
The differential dose-volume histogram (DVH) for the
GTV was exported for each dose plan. TCP calculations
were performed bin-wise using the Webb-Nahum model
(20) with parameters from reference (21) (TCP Bedford)
and also the Geh et al (8) model (TCP Geh). NTCP
modeling was carried out for heart, using the whole-heart
volume model of Gagliardi et al (15), for the pericardium
(12), and for lung using the model parameters from De
Jaeger et al (22), which predict radiation pneumonitis (RP)
of grade 2 or higher (symptoms requiring steroids). In
addition, we applied a combined heart and lung irradiation
model (18) to calculate predicted risk of RP in these pa-
tients, where the dose to the “hottest” 10% of the heart
volume (D10H), and the mean lung dose (MLD) in Gy are
used to calculate NTCP
NTCPZ
1
1þ expð xÞ
where
xZ0:0234D10H þ 0:0649MLD 3:5
As the values of dose-volume metrics, TCP and NTCP
across all patients were not normally distributed for all sets
of data (Shapiro-Wilk test), we used the Wilcoxon signed
rank test to compare RA50 versus RA62.5 plans for NZ21
patients. Data were analyzed using SPSS, version 20.0.0
(IBM), and results are reported as median (range) values,
with Z and P listed in Table 3.
Results
Dose boosting to 62.5 Gy with adequate target dose
coverage was possible for 20 out of 21 patients. For patient
21 (largest PTV, with 18.6% of PTV1 in lung) only 90.5%
coverage by the 95% isodose contour for PTV1 was ob-
tained. For all other patients the minimum V95% was
94.7% (RA62.5) versus 95.3% (RA50). For 4 additional
Table 3 Comparison of dose-volume metrics, TCP, and NTCP values*
Dose-volume
Plan
Median RA50 (range) Median RA62.5 (range)
RA62.5-RA50 (Wilcoxon
signed-rank test)
PTV1
V95% 98.3 (95.3-100) 96.7 (90.5-98.7) Z Z 2.63, P<.001
PTV2
V95% 97.2 (93.9-99.3)
TCP Geh et al (8) (%) 38.2 (37.6-39.6) 56.3 (55.1-57.2) Z Z 4.02, P<.001
TCP Bedford et al (21) (%) 40.3 (39.2-43.2) 71.7 (70.1-72.9)
Lung
Mean dose (Gy) 12.6 (8.4-18.2) 13.3 (8.4-17.9) Z Z 3.77, P<.001
V13Gy (%) 42.2 (19.7-68.6) 46.4 (19.7-68.8) Z Z 3.82, P<.001
V20Gy (%) 12.6 (5.9-29.9) 15.9 (5.8-29.1) Z Z 3.74, P<.001
NTCP (%) De Jaeger et al (22) 6.5 (3.9-12.9) 7.5 (3.9-12.6) Z Z 3.81, P<.001
NTCP (%) Huang et al (18) 14.2 (10.9-22.0) 15.5 (10.8-21.5) Z Z 3.84, P<.001
Heart
Mean dose (Gy) 20.4 (13.2-27.9) 20.3 (12.9-30.0) Z Z 1.41, PZ.16
V30Gy (%) 16.6 (10.3-33.1) 18.0 (10.5-38.1) Z Z 2.38, PZ.02
NTCP (%) Gagliardi et al (15) 4.4 (2.3-10.4) 5.6 (2.5-14.8) Z Z 3.98, P<.001
Pericardium (1cm inner)
Mean dose (Gy) 20.8 (13.8-27.9) 22.0 (14.2-29.6) Z Z 2.86, PZ.004
V30Gy (%) 19.6 (12.1-33.4) 20.7 (12.3-35.0) Z Z 3.29, PZ.001
V45Gy (%) 10.9 (6.5-23.2) 10.7 (6.0-23.7) Z Z 1.14, PZ.25
CordPRV
Dmax 0.1 cc (Gy) 34.9 36.1 Z Z 2.54, PZ.01
Abbreviations: CordPRVZ Cord planning organ at risk volume; DmaxZ maximum dose; NTCPZ normal tissue complication probability; PTVZ
planning target volume; RA50Z RapidArc boost to 50 Gy; RA62.5Z RapidArc plan with boost to 62.5 Gy; TCPZ tumor control probability; V45GyZ
volume receiving 45 Gy.
* Although the median values for dose to organs at risk for RA50 and RA62.5 plans are statistically different (P<.05), except for heart mean dose, the
differences in median dose across all patients are not clinically significant.
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to the GTV without exceeding other dose constraints.
Failure was due to lung V20Gy > 25% (patient 16) and mean
heart dose > 25 Gy (patients 7, 11, and 17). The dose
escalation strategy was therefore successful for 16/21
(76%) of patients.
The calculated TCP (Table 3) increased by 18% (from
38.2% to 56.3%) on average for the Geh model, and 31%
(from 40.3% to 71.7%) on average for the Bedford model.
Figure 1 shows patients listed in order of increasing PTV1
size and illustrates the general trend of increased irradiation
of the lung with increasing target volume size, although
mean lung dose is <20 Gy for all patients, and the average
increase with dose escalation is less than 1 Gy. The lung
V20Gy constraint was exceeded only for patients 16 and 21
(RA50 and RA62.5 plans), who have the highest percentage
of lung overlap in PTV1 of 2.5% and 3.2% respectively
(Table 1). Lung V13Gy shows an average increase of 4.2%
(Table 3) for the higher dose plans.
The SIB plans (RA62.5) result in an increase on average
of less than 1 Gy in mean dose to heart and pericardium.
Irradiation of the heart was not directly dependent on tumor
size (Table 1), but on the overlap with the PTV1 volume
(Fig. 2a). Patients 7, 11, and 17 have the highest % heart
overlap in PTV1 (9.6%, 16.5%, and 11.3% respectively)and mean heart dose was exceeded when the boost dose
was applied (plan RA62.5). For patient 11, the mean heart
dose constraint could not be met for either plan, due to the
GTVabutting the heart contour for this patient. Heart V30Gy
was well below the 45% limit for all patients. Mean dose to
the pericardium inner rind (12) was less than the recom-
mended 27.1 Gy dose constraint for all patients except
patient 11 (27.7 Gy) and patient 21 (27.9 Gy).
Heart mortality predicted using the criteria by Gagliardi
et al (15) showed a statistically significant increase of (on
average) 1.2% with increased dose to the GTV (Table 3),
though the predicted increase in heart mortality for some
individual patients can be larger (Fig. 2b) due to overlap of
heart with PTV1 (listed in Table 1). NTCP modeling for
pericardial effusion (12) applied to the pericardial structure
predicted a risk of pericarditis of zero for all patients.
For lung, the changes in NTCP (22) vary from patient to
patient (Fig. 1b). On average, risk of grade 2 (or higher)
radiation pneumonitis increased from 6.5% (RA50) to 7.5%
(RA62.5) P<.001 (Table 2). Patients 20 and 21 with large
PTV show no increase in predicted lung NTCP with higher
GTV dose, due to the trade-off with lower target coverage.
Using the combined heart and lung irradiation model for
radiation pneumonitis (23), the predicted risks of RP are
greater than for the lung only model, though the increase in
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Fig. 1. (a) Lung V20Gy values for each patient in order
of increasing PTV size for plans RA50 (black bars) and
RA62.5 (gray bars). The dose-volume constraint of 25% is
shown as a dashed line. (b) Lung NTCP was calculated
using the model parameters of De Jaeger for plans RA50
(black bars) and RA62.5 (gray bars) for each patient. NTCP
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Fig. 2. (a) Mean heart dose (Gy) for each patient for
plans using RA50 (black bars) and RA62.5 (gray bars). The
dose-volume constraint of 25 Gy is shown as a dashed line;
(b) predicted heart NTCP for each patient using the whole
heart contour and the NTCP model from Gagliardi et al
(15). NTCP Z normal tissue complication probability;
RA50Z RapidArc plan to 50 Gy; RA62.5Z RapidArc plan
with boost to 62.5 Gy.
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(median NTCP: 14.2% [RA50] versus 15.5% [RA62.5]
P<.001).Discussion
Our analysis of the dose-volume metrics and radiobiolog-
ical modeling of dose escalation for esophageal cancer
suggests that a significant increase (þ18%) in tumor con-
trol can potentially be achieved with only a modest increase
in the risk of cardiac and lung toxicities for 76% of patients
in our study of a subset of the SCOPE clinical trial data-
base. Other authors have also shown that IMRT may reduce
dose to critical structures such as heart and coronary ar-
teries, when compared to conformal radiation therapy
techniques (24, 25), but our study is the first to useradiobiological modeling to estimate both the level of dose
escalation, and to predict heart and lung toxicities arising
from this increase in dose. Patient outcomes and dose
response will be monitored in the proposed randomized
clinical trial investigating dose escalation for esophageal
cancer (SCOPE-2).
The results of our analysis are, of course, dependent on
the choice of the dose-volume and radiobiological param-
eters and models used, and we have therefore used a range
of models and values from the literature. We have also
shown that the relative comparison of 2 fractionation
schemes is valid using 2 independent TCP models,
although the absolute values of predicted TCP may be
different, depending on the model parameters. By
comparing fraction schedules with the same duration, we
have also limited any error due to clonogenic repopulation
rates and uncertainty in kick-off time. Both TCP models
assume an identical dose response for adenocarcinomas and
squamous cell esophageal cancers, and our analysis
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the GTV. If the 0.5 cm margins applied to create the boost
volume around the GTV are insufficient to ensure adequate
dose coverage in the presence of tumor motion, this may
reduce the predicted increase in TCP, such that these values
represent the upper limit of the benefits conferred by dose
escalation.
Recent data from cine-MRI suggest a margin of 10.7 
0.4 mm in the cranial-caudal direction might be required to
cover 95% of tumor movement (26), but this would imply
an increase in dose to a significant portion of esophagus
located immediately superior and inferior to the primary
tumor, which may be a dose limiting factor in these pa-
tients. A margin of 0.5 cm was chosen in order to limit the
volume of “healthy” esophagus irradiated and to generate a
gradual drop-off in dose around the GTV. Data available in
the literature concerning the dose-volume relationship for
esophageal toxicity are from lung cancer patients (27, 28),
and it is not clear if the dose limits would be applicable to
patients with esophageal tumors. The results of a clinical
trial using hypofractionation in non-small cell lung cancer
(NSCLC) observed several grade 4 and 5 toxicities to
central structures when doses were increased to 75 Gy and
above but suggested 63.25 Gy/25 fractions should be well-
tolerated in terms of both acute and late toxicity (29), which
would suggest our proposed dose prescription of 62.5 Gy/
25 fractions may be acceptable. We have in addition used
stricter dose-volume constraints for plan optimization than
specified in the original SCOPE protocol, but careful
monitoring of esophageal toxicity during and after CRT
will be necessary for the safe application of any dose
escalation scheme.
For patients with larger PTVs with significant overlap in
lung (>540 cm3 and 18% overlap in our patient subset),
dose escalation using arc therapy may not be possible
without a significant increase in dose delivered to sur-
rounding lung. Hybrid static IMRT/RA irradiation tech-
niques might provide better lung sparing for these patients
(30). Also, the CTVs created in our study to encompass
regions of microscopic tumor spread, were generated using
isotropic geometrical margins. A further improvement
would be to delineate the CTV for each patient on each
slice of the CT scan to respect known anatomical bound-
aries, and thereby reduce the amount of normal tissue
irradiated.
For patients where the heart overlaps the PTV (>8.5%
heart in PTV overlap for this subset) dose escalation would
exceed recommended cardiac dose constraints, even using
advanced treatment planning and delivery techniques. Dose
to the pericardium might be considered more relevant for
modeling of acute toxicity (pericardial effusion) than dose
to the whole heart, although our data suggests that for all
patients, dose to pericardium is well within the various
dose-volume constraints recommended in the literature (11-
13). This may be due to the use of IMRT/RA, which de-
livers significantly lower dose to heart than previous 2D or
3D conformal radiation therapy techniques. We havetherefore used the whole heart to model cardiac mortality,
although as a long-term effect (5-10 years), this may be less
clinically relevant for esophageal cancer patients where
median survival is around 25 months (31).
Acute radiation-induced lung toxicity may therefore be
more important for these patients and our data suggest that
even with higher dose to the tumor, the increase in risk of
radiation pneumonitis is small, and might be considered
acceptable for patients with limited organ-at-risk overlap
inside the PTV (<8% heart volume and <2.5% lung vol-
ume overlap for this study), given the predicted gains in
tumor control. Concomitant irradiation of the heart or a pre-
existing cardiac pathology have recently been identified as
risk factors in radiation pneumonitis (18), and this should
be assessed for each patient during planning.Conclusions
Radiobiological modeling suggests that dose escalation to
the GTV in esophageal cancer has the potential to produce
significant gains in tumor control with only a minor in-
crease in lung or heart toxicity for the majority of patients.
The relationship between tumor response and normal tissue
toxicity during dose escalation should be carefully vali-
dated in clinical trials.References
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